The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
about
The role of HDAC6 in cancerThe protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent mannerThe multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic targetHistone deacetylase 6 plays a role as a distinct regulator of diverse cellular processesPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerNAD+ and SIRT3 control microtubule dynamics and reduce susceptibility to antimicrotubule agents.Targeting protein prenylation for cancer therapyBortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.HDAC6 inhibition restores ciliary expression and decreases tumor growthSelective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agentsLipid posttranslational modifications. Farnesyl transferase inhibitors.C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Farnesyltransferase inhibitors reverse taxane resistanceInhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancersPhase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.Lonafarnib in cancer therapy.Emerging drugs to replace current leaders in first-line therapy for breast cancer.HDAC6 and ovarian cancer.Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.The molecular genetics of breast cancer and targeted therapyUbiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.Manipulating the epigenome for the treatment of urological malignancies.Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy.Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine.Advances in personalized therapy for lung cancer.Translational genomics and head and neck cancer: toward precision medicine.Chemotherapy Resistance in Lung Cancer.Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells.Microtubule stability and MAP1B upregulation control neuritogenesis in CAD cells.Rotenone Induces the Formation of 4-Hydroxynonenal Aggresomes. Role of ROS-Mediated Tubulin Hyperacetylation and Autophagic Flux Disruption.
P2860
Q21296746-962F1990-99F9-494A-AF70-EB081DC3C130Q24312194-B9677EE2-0B7A-4622-8A40-242D8070C37AQ26744292-E40AF741-151D-48A6-A421-5E368AB0A225Q26830233-1939F3C0-20D4-438D-A973-5BC5A257D4F2Q28240692-500774CB-6165-4A57-B2BF-7C9E3A773E31Q28265589-D5BDF5B5-9DC7-42C1-82CB-215C66A7CE6BQ28396304-E4CAA5D8-744D-4DFE-BDA9-EC8FD0E1756EQ30581187-228F7483-16A8-481E-98CE-C63F6C04C696Q33679239-118111B3-8F8C-4D2C-9847-09D5E5C152ECQ33798624-CABA75C3-B4DB-4875-9CE3-4533DBA30535Q34035361-B974F322-75F6-4BA9-9EAF-F6154D22A08BQ34358718-55300DAA-A6D6-48F6-B39F-0451E2BB70B0Q34651253-36E15968-BFEC-4B1B-8DA1-BAF611AD0616Q34797621-E1E677B9-6A52-484C-88FC-930A50007904Q35091519-FF1A459A-9FF6-41AD-9B0C-4F309CDB66E0Q35774556-5A540FC5-1F77-4C9E-84C4-357F7C308E46Q36282749-C19D6211-B089-4A0E-970D-87757C229B8EQ36354259-71E7D1A2-8247-42B9-B376-9DC0CC8E170CQ36363994-9066393F-641D-4BCE-B4AF-296823648FC0Q36491847-5C0F0939-795C-4542-A744-2B6291FB533AQ36580598-DB65C32C-B718-49E1-B32A-967E1E266209Q36913610-83AA5770-13EF-4F4E-8D15-D549C5FD0C9EQ36946766-46CBF49A-2371-41D8-A918-4CF0010A6771Q36998251-9A43CB2D-B69C-4D25-8FCA-48B5421D665CQ37290512-C3FF2492-DABD-4F4F-A948-578FC047FEFEQ37347868-AAB6C1D3-7448-4A46-87D7-AF1F6CC9BB87Q37396876-5688628E-CBEA-4249-83E4-7B9011A26D28Q37524412-E2DE7BEC-EA42-47D0-BA99-346FC1F9EF7AQ37631283-1CBFE2CC-410C-4674-9D23-E3633ECA13FBQ37716468-5138F539-FDA8-4D9A-B155-9B3C84AB844CQ37723277-AF55388D-5A6A-4093-A4F5-6ECE8A5FF645Q37734520-7437E768-EA0F-48C8-BFD9-743D549D3246Q38127786-60378FE8-6DB8-4BE1-BBA8-5C70D5004A02Q38241804-7B13202F-6664-4BEB-A741-291D22BD0422Q38669287-CCB84362-F569-4D7E-812B-3D23361BE9EBQ39474160-D1ECD1DE-4B19-4C86-AEA8-A25EE0C22D33Q39655498-3B3AE084-987C-46D0-A1B2-4397C346F113Q39747031-4B6FA404-F299-408F-A802-AA2E47694F8BQ40241269-1A652A4F-12C1-427F-9DAD-BA3CE3FDAE50Q45291266-89C962E0-495E-4F4A-B85E-2F66E89DAC6B
P2860
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The synergistic combination of ...... unctional tubulin deacetylase.
@ast
The synergistic combination of ...... unctional tubulin deacetylase.
@en
type
label
The synergistic combination of ...... unctional tubulin deacetylase.
@ast
The synergistic combination of ...... unctional tubulin deacetylase.
@en
prefLabel
The synergistic combination of ...... unctional tubulin deacetylase.
@ast
The synergistic combination of ...... unctional tubulin deacetylase.
@en
P2093
P2860
P1433
P1476
The synergistic combination of ...... unctional tubulin deacetylase.
@en
P2093
Adam I Marcus
Adel El-Naggar
Aurora O'Brate
Ernest Hamel
Fadlo R Khuri
Jason Wong
Michael Nivens
Paraskevi Giannakakou
Tso-Pang Yao
P2860
P304
P356
10.1158/0008-5472.CAN-04-3757
P407
P577
2005-05-01T00:00:00Z